36C25726Q0002.pdf

PAGE 1 OF 1. REQUISITION NO.

2. CONTRACT NO. 3. AWARD/EFFECTIVE DATE 4. ORDER NO. 5. SOLICITATION NUMBER 6. SOLICITATION ISSUE DATE

a. NAME b. TELEPHONE NO. (No Collect Calls) 8. OFFER DUE DATE/LOCAL

TIME

9. ISSUED BY CODE 10. THIS ACQUISITION IS UNRESTRICTED OR SET ASIDE: % FOR:

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

WOMEN-OWNED SMALL BUSINESS

(WOSB) ELIGIBLE UNDER THE WOMEN-OWNED

SMALL BUSINESS PROGRAM

EDWOSB

8(A)

NAICS:

SIZE STANDARD:

11. DELIVERY FOR FOB DESTINA-

TION UNLESS BLOCK IS

MARKED

SEE SCHEDULE

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER

DPAS (15 CFR 700)

13b. RATING

14. METHOD OF SOLICITATION

RFQ IFB RFP

15. DELIVER TO CODE 16. ADMINISTERED BY CODE

17a. CONTRACTOR/OFFEROR CODE FACILITY CODE 18a. PAYMENT WILL BE MADE BY CODE

TELEPHONE NO. UEI: EFT:

PHONE: FAX:

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER

18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED

SEE ADDENDUM

19. 20. 21. 22. 23. 24.

ITEM NO. SCHEDULE OF SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

(Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA 26. TOTAL AWARD AMOUNT (For Govt. Use Only)

27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA ARE ARE NOT ATTACHED.

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA ARE ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _______________ 29. AWARD OF CONTRACT: REF. ___________________________________ OFFER COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND DATED ________________________________. YOUR OFFER ON SOLICITATION DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY (BLOCK 5), INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED SET FORTH HEREIN IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER)

30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT) 30c. DATE SIGNED 31b. NAME OF CONTRACTING OFFICER (TYPE OR PRINT) 31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION (REV. NOV 2021)

PREVIOUS EDITION IS NOT USABLE Prescribed by GSA - FAR (48 CFR) 53.212

7. FOR SOLICITATION

INFORMATION CALL:

STANDARD FORM 1449

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES

OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30

504-26-2-044-0006

36C25726Q0002 08-18-2025

Jose Campa 210-617-5300 x246260 09-08-2025

10:00 CDT

36C257

Department of Veterans Affairs Network Contracting Office 17 5441 Babcock Road Ste. 302 San Antonio TX 78240

X

Y

621511

$32.5 Million

N/A

X

36C504

Department of Veterans Affairs Amarillo VA Health Care System P&LMS Section 6010 Amarillo Boulevard, West Amarillo TX 79106

36C257

Department of Veterans Affairs Network Contracting Office 17 5441 Babcock Road Ste. 302 San Antonio TX 78240

This is accomplished through the Tungsten Network located at:

http:www.fsc.va.gov/einvoice.asp This is mandatory and the sole method for submitting invoices

(877) 353-9791 (512) 460-5540

See CONTINUATION Page

Reference Lab Testing for the Amarillo VA Health Care System

Please see:

1. Statement of Work on page 5.

2. Price/Cost Schedule on page 23.

3. Addendum To Far 52.212-1 on page 44.

4. 52.212-2 Evaluation-Commercial Products and Commercial Services on page 45.

Technical Questions Cutoff: Friday, 08-22-25 at 1:00PM/CDT.

See CONTINUATION Page

X X

X 1

Jose Campa Contracting Officer

36C25726Q0002

Table of Contents

SECTION A

A.1 SF 1449 SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS

AND COMMERCIAL SERVICES

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

B.2 STATEMENT OF WORK

B.3 PRICE/COST SCHEDULE

ITEM INFORMATION

B.4 INTRODUCTION

B.5 TERMS AND CONDITIONS

B.6 ADMINISTRATIVE DATA

B.7 PRICING DATA

B.8 NONPERSONAL SERVICES

B.9 AUTHORIZED LIMITS

B.10 OBLIGATION OF FUNDS

B.11 PERIOD OF PERFORMANCE

B.12 AUTHORIZED INDIVIDUALS

B.13 ORDER FORMAT

B.14 AUTHORIZED REPRESENTATIVES

B.15 FEDERAL HOLIDAYS

B.16 INVOICES

B.17 PRECEDENCE

SECTION C - CONTRACT CLAUSES

C.1 FSS RFQ INTRODUCTORY LANGUAGE

C.2 52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)

C.3 52.212-5 CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT

STATUTES OR EXECUTIVE ORDERS—COMMERCIAL PRODUCTS AND

COMMERCIAL SERVICES (JAN 2025)

C.4 52.217-8 OPTION TO EXTEND SERVICES (NOV 1999)

C.5 52.217-9 OPTION TO EXTEND THE TERM OF THE CONTRACT (MAR 2000) ... 38

C.6 VAAR 852.242-71 ADMINISTRATIVE CONTRACTING OFFICER (OCT 2020) ... 38

SECTION D - CONTRACT DOCUMENTS, EXHIBITS, OR ATTACHMENTS

SECTION E - SOLICITATION PROVISIONS

E.1 52.252-1 SOLICITATION PROVISIONS INCORPORATED BY REFERENCE (FEB

1998)

E.2 52.204-24 REPRESENTATION REGARDING CERTAIN TELECOMMUNICATIONS

AND VIDEO SURVEILLANCE SERVICES OR EQUIPMENT (NOV 2021)

E.3 52.209-7 INFORMATION REGARDING RESPONSIBILITY MATTERS (OCT 2018)

E.4 ADDENDUM to FAR 52.212-1 INSTRUCTIONS TO OFFERORS—COMMERCIAL

PRODUCTS AND COMMERCIAL SERVICES

E.5 52.212-2 EVALUATION—COMMERCIAL ITEMS (OCT 2014)

E.6 52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS—

COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES (MAY 2024)

E.7 52.233-2 SERVICE OF PROTEST (SEP 2006)

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

1. Contract Administration: All contract administration matters will be handled by the following individuals:

a. CONTRACTOR: TBD

b. GOVERNMENT: Jose Campa, Contracting Officer 36C257

Network Contracting Office 17

5441 Babcock Road Ste. 302

San Antonio TX 78240

2. CONTRACTOR REMITTANCE ADDRESS: All payments by the Government to the contractor will be made in accordance with:

[X] 52.232-33, Payment by Electronic Funds Transfer—System For Award Management, or

[] 52.232-36, Payment by Third Party

3. INVOICES: Invoices shall be submitted in arrears:

a. Quarterly []

b. Semi-Annually []

c. Other [X] Monthly

4. GOVERNMENT INVOICE ADDRESS: All Invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests.

ACKNOWLEDGMENT OF AMENDMENTS: The offeror acknowledges receipt of amendments to the Solicitation numbered and dated as follows:

AMENDMENT NO DATE

B.2 STATEMENT OF WORK

1. GENERAL INFORMATION

1.1. Title of Project: Reference Laboratory Testing Services for Amarillo VA Health Care System

1.2. Background: The Amarillo VA Health Care System (AVAHCS) and affiliated sites including associated Community Based Outpatient Clinics (CBOC) and Health Clinics require referral laboratory services for diagnostic testing not performed in house. These services are essential for ensuring timely diagnosis, continuity of care, and compliance with evidence-based clinical standards. AVAHCS serves a geographically dispersed Veteran population, including rural and remote communities, making access to comprehensive and reliable diagnostic testing a critical operational need. A formal reference laboratory contract is necessary to ensure continuity, reliability, and regulatory compliance in meeting these clinical demands through a structured, accredited, and performance-monitored partnership.

1.3. Scope of Work: This full-service reference laboratory contract will provide services required for specimen testing, interpretation, testing supplies, courier, customer service, system interfaced lab result reporting services and verification of certification for test results. Services shall include analytical testing & results reporting for clinical, anatomical, and cytological modalities for any/all sample types, including but not limited to blood, urine, tissue, and other body fluids and will include courier services for specimen transportation from AVAHCS sites to reference laboratory as needed. This requirement will ensure accurate and timely test results are made available to the AVAHCS healthcare providers to deliver high-quality healthcare to AVAHCS Veterans.

This contract will support any test currently offered by the contractor or its subcontractor labs within their network. Due to the clinical unpredictability and diversity of test needs, it is not feasible to list every individual test. Instead, the contractor shall provide access to its full test menu, including newly developed or updated tests, without the need for amendment. Services include test performance, reporting, consultation, supply provision, and maintenance of local patient service centers (PSCs) in Amarillo, Lubbock, and Clovis to support Veteran specimen collection in the event VA phlebotomy services are unavailable or disrupted at any of the primary locations. Test results must be returned via secure interface, with the contractor completing interface implementation within 60 days of contract award.

1.4. Performance Period:

1.4.1. January 1, 2026 – December 31, 2026 (Base Year), with four one-year options (through December 31, 2030).

1.5. Places of Performance:

1.5.1. Thomas E. Creek VA Medical Center: 6010 Amarillo Blvd W, Amarillo, TX 79106

1.5.2. Lubbock VA Community Based Outpatient Clinic: 3510 4th St, Lubbock, TX 79415

1.5.3. Childress VA Clinic: 2305 Avenue F Northwest, Suite 900 Childress, TX 79201-2113

1.5.4. Clovis VA Clinic: 921 East Llano Estacado Boulevard Clovis, NM 88101-

1.5.5. Dalhart VA Clinic: 325 Denver Avenue Dalhart, TX 79022-2711

2. REQUIREMENTS:

2.1. Specific Tasks

2.1.1. The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing for the specific range of referral testing within their capability.

2.1.2. Services shall include the performance of analytical testing as defined by the Laboratory's reference test manual, the reporting of analytical test results and consultative services as required.

2.1.3. All requirements and provisions defined in the specifications of this solicitation will apply to any laboratory, i.e., branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory.

2.1.4. Generally, the AVAHCS facilities will be responsible for specimen collection and will provide laboratory specimens prepared according to the Reference Laboratory's user’s manual, identified, and labeled for testing.

2.1.5. Provision local patient service centers (PSCs) in Amarillo TX, Lubbock TX, and Clovis NM to support Veteran specimen collection in the event VA phlebotomy services are unavailable or disrupted at any of the primary locations.

2.1.6. Reference Laboratory must be capable of arranging daily specimen pickup at all AVAHCS affiliated hospitals and clinics (listed in section 1.6).

2.1.7. Reference Laboratory shall provide laboratory services to include pre-analytic processing as defined in Reference Laboratory published user’s manual, analysis, reporting of analytic results and interpretation of analytic clinical results. The number of tests requested under this contract will change throughout the life of the contract. The volumes or amounts shown in the solicitation are estimates only and impose no obligation on the VA.

2.1.8. The Reference Laboratory shall also provide the following support services:

supplies, customer service, reporting services, courier and verification of certification.

2.1.9. Provide all necessary supplies as defined in the laboratory user manual, to include, but not limited to the following:

2.1.9.1. Requisition forms or agreed computer ordering system.

2.1.9.2. Specimen containers & collection kits.

2.1.9.3. Specimen requirements for specimen collection & specimen processing.

2.1.9.4. Methodologies and reference ranges.

2.1.9.5. Expected turn-around times.

2.1.9.6. All forms, including authorization of consent for genetic testing, informed consent, and chain of custody.

2.1.10. The Reference Laboratory shall provide to the VA Facilities the supplies and equipment within one (1) week of receipt of the delivery order. The VA Facilities will request replenishment of supplies from the Reference Laboratory on an as needed basis via telephone or fax. A confirmation of the order shall be supplied to the VA within 24 hours.

2.1.11. All supplies shall be shipped by contractor to AVAHCS and/or to AVAHCS affiliated facility.

2.2. Electronic Interface

2.2.1. If awarded the Reference Laboratory agrees to a transition period for providing a fully functioning interconnection for exchanging data between our current system “VISTA “to the Reference Laboratory's electronic lab information system. During this time the Reference Laboratory will supply the VA Facility with available test menu and agrees to receive test orders.

The Reference laboratory agrees to work with VISTA system to ensure connectivity and aid the VA. Test orders that were created for testing the interface system will be at no charge.

2.2.2. Vendors shall have solidified VISTA electronic test list ready to go for AVAHCS to be used upon 1/1 (PoP start) and data transfer ready to be used upon start of POP 1/1.

2.2.3. System drivers must be compatible with the VA’s VISTA system. The server and interface software will be owned and maintained by the Reference Laboratory. The Reference Laboratory must have a signed MOU (Memorandum of Understanding) with the VA Network and Security Operations Center (NSOC).

2.2.4. This interconnection shall be protected using VA approved encryption algorithms and products as required and in compliance with HIPAA guidelines. Connections at each end shall be located within a controlled access facility. All access shall be controlled by authentication methods to validate approved users.

2.2.5. Reference Laboratory shall notify VA Facilities of any specimen problems or discrepancies from the submitted manifest within 24 hours after shipping.

2.3. Testing Methodology, Reference and Turn Around Time

2.3.1. Routine test results shall be reported within the specified turnaround time

(TAT) which is defined from time of specimen receipt by the contractor to when results are available. If testing is going to be delayed and the results will not be within published TAT, notify the VA Facilities of the new estimated TAT within 12 hours.

2.3.2. Testing methodology and reference ranges for a test must be defined in the Reference Laboratory user manual and/or website. Reference Laboratory shall advise facility of any changes in methodology, procedure, reference ranges and any new tests introduced 30 days in advance.

2.3.3. Reference Laboratory agrees to maintain the minimum acceptable service, reporting systems and quality control. Exception handling: Reference Laboratory will notify VA Facilities Laboratory Service within 12 hours of any problems with specimens received.

2.3.4. The VA Facilities will provide laboratory specimens prepared according to the Reference Laboratory's user’s manual, identified, and labeled for testing.

2.3.5. Critical Value test results shall be reported immediately. Telephoned results will be confirmed with a follow-up by vendor via fax.

2.3.6. The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing. All requirements and provisions defined in the specification of this solicitation will apply to any laboratory, i.e. branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory.

2.3.7. Operate a dedicated, temperature-controlled courier fleet for specimen pickups.

2.4. Customer Service & Patient Information Safety

2.4.1. The reference laboratory will provide VA Laboratory with a means of communication to permit immediate inquiry regarding the status of pending tests or specimen problem, 24 hours per day, 7 days per week.

2.4.2. The reference laboratory shall provide names and telephone numbers of Technical Directors and Pathologists available to provide information.

2.4.3. Reference lab agrees not to use or disclose Protected Health Information (PHI) other than as permitted or required by the agreement or as required by law.

2.4.4. Reference lab agrees to use appropriate safeguards to prevent use or disclosure of the PHI other than is provided for by this agreement.

2.4.5. Reference lab agrees to report immediately any breach of safeguards and to mitigate any harmful effect related to the use or disclosure of PHI by the Reference Laboratory or any of its agents, including subcontractors.

2.4.6. The reference lab will comply with reporting test results with the specified time frame in accordance with the nature of the testing, following all regulatory requirements for reporting of patient results. Test results shall be reported within specified times established by the reference laboratory.

Critical value test results shall be reported immediately by telephone.

Results will be sent to the VA via a secure means and in compliance with Health Portability and Accountability Act (HIPPA) guidelines.

2.4.7. The contractor will provide test related information that is readily available and easy to access to help select the proper test, interpret results, and build tests in VISTA for interconnection for electronic data interchange (EDI).

2.4.8. The contractor will provide a 24-hour response time to all inquiries made by P&LMS.

2.4.9. The Reference Laboratory courier shall be responsible for transporting and storing specimens in such a manner as to ensure integrity of the specimen where applicable and protect patient sensitive information.

2.4.10. The Reference Laboratory shall provide routine scheduled specimen pickup at a time mutually agreed upon by the AVAHCS facilities.

Specimens will be picked up daily and weekends, if needed, at no extra charge to the government.

2.5. Delivery and Reporting

2.5.1. Billing summaries shall begin the first day of the month and include the last day of the month.

2.5.2. Tests referred to another laboratory shall be at no additional transfer charge or confirmation charge to the government.

2.5.3. Deliveries must be accompanied by a delivery ticker or sales slip that contains the following information as a minimum:

2.5.3.1. Vendor Name

2.5.3.2. Applicable FSS contract number

2.5.3.3. BPA Number, Task order number, and Purchase Order number

2.5.3.4. Date of Purchase

2.5.3.5. Date of Shipment

2.5.3.6. Description of item

2.5.3.7. Quantity of each item

2.5.3.8. Unit price and extended (quantity x unit price) price for each item

2.5.4. The Reference Laboratory shall provide a quarterly and end of year report showing sample issues, facility usage, and cost savings generated during the reporting period. The report will be due 45 days after the close of each government fiscal quarter.

2.6. **NOTE: See Section 'Contract Restrictions' regarding marketing limitations.**

3. PERFORMANCE MONITORING

3.1. To minimize administrative burden, the following performance standards will be used for tracking, based on easily accessible documentation such as invoices, email logs, supply confirmations, and scheduled reports. The Contractor shall be subject to the following standards and acceptable quality levels (AQL):

3.1.1. Standard 1 – Invoice Accuracy: Monthly invoices must reflect accurate

CPT codes, units, and test names. Acceptable Quality Level (AQL): 95%

3.1.2. Standard 2 – Critical Result Notification: Panic values must be reported verbally to AVAHCS within 1 hour of result verification, followed by written confirmation. AQL: 100%

3.1.3. Standard 3 – Customer Service Response Time: All test-related inquiries must be addressed within 24 business hours. AQL: 100%

3.1.4. Standard 4 – Supply Delivery: Requested supplies must be confirmed within 24 hours and delivered within 7 calendar days. AQL: 95%

3.1.5. Standard 5 – Quarterly Report Submission: Usage and issue reports must be submitted within 45 days of each fiscal quarter's close. AQL: 95%

4. LICENSING AND ACCREDITATION

4.1. Reference Laboratory shall provide copies of all licenses, permits, accreditation and certificates required by law. Laboratory Director shall be a licensed American Board of Pathology certified pathologist or appropriately certified bio-analyst.

4.2. All medical facilities providing laboratory services under the contract must possess a valid state license and meet JC standards as well as CLIA requirements and standards of the College of American Pathologists (CAP).

4.3. The Reference Laboratory shall make sure employees have current and valid professional certifications before starting work under this contract.

4.4. The Reference Laboratory staff shall meet personnel qualifications required by Clinical Laboratory Improvement Act (CLIA) '88 Guidelines. Contractor shall participate in proficiency testing (PT) programs such as CAP or equivalent and provide PT performance summaries and quality control documentation upon request by the COR or designated government representative.

4.5. The Government’s reserves the right to request information or certification from the contractor verifying they comply with this contract requirement. If discovered the contractor is not in compliance with this requirement the contract shall be terminated for cause in accordance with clause 52.212-4.

5. WORK SITE ACCESS

5.1. Coordinate access with the COR during normal hours (8:00 AM – 4:30 PM, Monday–Friday, excluding federal holidays).

5.2. Afterhours access will be permitted as deemed necessary by both the Vendor or the COR and/or or laboratorian.

5.3. Comply with VA security protocols, including background checks and ID verification for personnel, if necessary.

6. EXECUTION

6.1. Perform all work in a safe and efficient manner per OSHA (29 CFR 1910.1030), FDA, and AABB safety guidelines, or other applicable standards.

6.2. Optimize delivery/pickup schedules to minimize disruption, prioritizing STAT requests.

6.3. Designate a 24/7 POC for COR communication and conduct weekly status meetings (virtual or in-person).

7. SECURITY

7.1. The contractor, their personnel, and their subcontractors shall be subject to the

Federal laws, regulations, standards, and VA Directives and Handbooks regarding information and information system security as delineated in this contract.

7.2. Comply with VA security protocols, including background checks and ID verification.

7.3. The C&A requirements do not apply, and that a Security Accreditation Package is not required.

7.4. Secure patient data per HIPAA and VA Directive 6500, with no Certification and Accreditation (C&A) required.

7.5. Ensure tamper-proof handling and transportation with chain-of-custody documentation.

8. BILLING AND INVOICING

8.1. Monthly billing and test report summaries shall begin on the first day of the month and include the last day of the month.

8.2. VA-FSC shall require the following information in compliance with the Prompt Pay

Act and Business Requirements.

8.2.1. Your Taxpayer ID number (TIN)

8.2.2. Your “Remit Address” information

8.2.3. The VA Purchase Order (PO) number

8.2.4. Your contact information: (Personal name, Email, and Phone)

8.2.5. Your VA Point of contact information (Personal name, Email, and Phone)

8.2.6. The Period of Performance dates (POP Beginning and Ending)

8.2.7. All discount information if applicable (Percent and Date Terms)

8.2.8. Reagents used with pricing per unit

8.2.9. No freight charges to be added to the invoice

8.3. Department of Veterans Affairs Financial Service Center:

8.3.1. Phone:1-877-353-9791

8.3.2. Email: vafscched@va.gov

8.4. AVAHCS shall not be responsible for payment of services and or supplies which were not requested in accordance with the contract.

8.5. AVAHCS will NOT pay for tests that are not clearly identified by product number on the invoice.

8.6. Invoices are to be separate for Amarillo and Lubbock laboratories, but the usage of the same PO number is acceptable for billing purposes.

8.7. Invoices will be electronically submitted to the Tungsten website at:

8.7.1. http://ww.tungsten-network.com/uk/en/

8.7.2. Tungsten direct vendor support number is 877-489-6135 for VA contracts.

8.8. All invoices submitted through Tungsten to VA-FSC should mirror your current submission of Invoice.

Exhibit A: AMARILLO VA HEALTH CARE SYSTEM MONTHLY TEST VOLUME ESTIMATES.

(Note: Total monthly estimated test volume is across all sites)

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

**ADULT FOOD ALLERGY PROF 7 1

**ALCOHOL METAB, QN, U 8 1

**DM BARBITURATES QN U 1 1

**DM BENZO QN U 19 1

**DM BUP AND NAL QN, U 1 1

**DM COCAINE MET QN U 9 1

**DM FENTANYL,QN,U 2 1

**DM MARIJUANA M QN U 60 3

**DM METHAMP ISOMERS,U 3 1

**DM MPHENIDATE M,QN,U 34 2

**DM OPI EXPANDED QN U 2 1

**DM OXYCODONE QN U 4 1

**DM ZOLPIDEM QN, UR 1 1

**GEN TOX LC/MS/MS, U 1 1

**HLA-A29 TYPING 1 1

**HLA-B51 TYPING 1 1

**HSV1/2 IGM,W/RFL CSF 1 1

**KAPPA/LAMBDA 24 HR U 1 1

**KAPPA/LAMBDA QT 3 1

**MYOGLOBIN, (U) 10 1

**PHARMACOGENOMICS PANEL 1 1

**PNEUMO AB PANEL 14 2 1

mailto:vafscched@va.gov http://ww.tungsten-network.com/uk/en/

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

**VIP 2 1

14 3 3 ETA PROTEIN 1 1

14-3-3 PROTEIN,CSF 1 1

17-OHPROGEST.LC/MSMS 7 1

21-HYDROXYLASE AB 1 1

3A ANDRO GLUCURONIDE 1 1

5 HIAA,24 HR W/CREAT 9 1

A-1-ANTITRYPSIN QN 35 2

ABL MUTATION 2 1

ACHR BINDING AB 80 3

ACHR BLOCKING 60 3

ACHR MODULATING AB 78 3

ACTH 116 5

ACTIN ANTIBODY (IGG) 2 1

ACYLCARNITINE PLASMA 2 1

ACYLGLYCINES IN UR 1 1

ADALIMUMAB ADA IBD 1 1

ADALIMUMAB LEVEL IBD 1 1

ADAMTS13 ACTIV.W/RFL 5 1

ADENOSINE DEAMINASE, PLEU 5 1

ADIPONECTIN 1 1

AEROBIC BACTERIA ID & S 10 1

ALBUMIN 314 12

ALDOLASE 120 5

ALDOSTERONE (U) 8 1

ALDOSTERONE,LC/MS 195 7

ALK PHOS ISOENZYMES 41 2

ALLERGY 2, SE 2 1

ALPHA 3 AB 20 1

ALPHA SUBUNIT 3 1

ALPHA THAL MUT ANAL 10 1

ALT 5 1

ALUMINUM, BLOOD 3 1

AMH, FEMALE 1 1

AMINO ACID FRAC, P 1 1

AMIODARONE 12 1

AMITRIPTYLINE 1 1

AMPHETAMINE QN,SERUM 5 1

AMPHETAMINES,QN,U 13 1

ANA TITER&PATTERN 19 1

ANA W/RFX 49 2

ANAEROBIC BACT. ID 11 1

ANAEROBIC ID& SUSCEP 1 1

ANCA SC W/RFL TITER 275 10

ANGIOTENSIN CONV ENZ 151 6

ANTI-DSDNA AB, EIA 173 7

ANTI-GM1 33 2

ANTI-HU AB,WB 1 1

ANTI-HU RFX/TITER/WB 1 1

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

ANTITHROMBIN III ACT 67 3

ANTITHROMBIN III AG 19 1

APC RESISTANCE 4 1

APOE ISOFORM, PLASMA 6 1

APOLIPOPROTEIN B 6 1

APOLIPOPROTEIN EVAL 24 1

AQP4 (NMO IGG) 16 1

AQUAPORIN 4 AB, CBA 1 1

ARSENIC (B) 72 3

ARSENIC (U) 1 1

ASP FUMIGATUS IGG AB 5 1

ASPERGILLUS ANTIGEN 9 1

AST 5 1

ATAXIA,COMP EVAL 1 1

ATYP P-ANCA TITER 14 1

B.HENSELAE IGG SCR 2 1

B.HENSELAE IGM SCR 2 1

B2-GLYCO I(IGA) 224 8

B2-GLYCO I(IGG) 224 8

B2-GLYCO I(IGM) 224 8

BCR ABL1 GENE QN PCR 21 1

BERYLLIUM;B 1 1

BETA-2-MICROGLOBULIN 179 7

BETA-GLOBIN COMPLETE (TM) 2 1

BICARBONATE;U 1 1

BILIRUBIN,BODY FLUID 7 1

BK VIRUS DNA,QN,PCR 8 1

BKV PCR, QUANT 57 3

BLADDER CANCER, FISH 1 1

BLASTOMYCES AB, ID 3 1

BP180 1 1

BRCA PANEL PLUS 1 1

BRCA(TM), COMP 1 1

BRUCELLA IGG,IGM 6 1

BULLOUS PEMPHIGOID 1 1

BUPRENORPHINE SERUM 7 1

C DIFF TOXIN W/REFL 10 1

C-ANCA TITER 1 1

C-PEPTIDE 152 6

C1 INHIBITOR, FUNCT 7 1

C1 INHIBITOR, PROTEIN 4 1

CA 15-3 13 1

CA 19-9 (CENTOCOR) 86 4

CA125 27 1

CA27.29 CHIRON/BAYER 18 1

CADMIUM (B) 2 1

CALCITONIN 13 1

CALCIUM, IONIZED 29 2

CALPROTECTIN,STOOL 122 5

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

CALR MUTATION 30 2

CAMPY CULTURE 1 1

CAMPYLOBACTER,ELISA 2 1

CARBOXYHEMOGLOBIN 2 1

CARDIOLIPIN IGA AB 216 8

CARDIOLIPIN IGG AB 221 8

CARDIOLIPIN IGM AB 218 8

CARDIOLP AB G/M/A 15 1

CARNITINE, LC/MS/MS 4 1

CAROTENE 2 1

CATECHOLAMINES 24HR 47 2

CATECHOLAMINES,PLASM 24 1

CCP AB IGG 383 14

CENTROMERE AB, EIA 7 1

CERULOPLASMIN 29 2

CHICKEN MEAT IGG 1 1

CHLAMYDIA PNEU.PNL 2 1

CHOLESTEROL,PLEUR.FL 5 1

CHROMIUM, BLOOD 1 1

CHROMOGRANIN A 25 1

CHROMOSOME, BLOOD 2 1

CITRIC ACID 24HR (U) 3 1

CK ISOENZYMES 21 1

CK, TOTAL 25 1

CLOSTRIDIUM DIF TBR QL 3 1

CMV DNA QN, PCR 16 1

CMV IGG AB 106 4

CMV IGM AB 106 4

COAG FACTOR IX ACT 2 1

COAG FACTOR V ACT 12 1

COBALT, S/P 1 1

COCCI AB TO TP/F AG 2 1

COCCIDIO AB, ID 11 1

COCCIDIOIDES AB, CF 11 1

COENZYME Q10 1 1

COLD HEMAGGLUTININS 2 1

COLLAGEN TYPE I CTX 22 1

COMP C3C4 2 1

COMPLEMENT C3C 1 1

COMPLEMENT C4C 1 1

COMPLEMENT COMP C1Q 3 1

COMPLEMENT, (CH50) 2 1

COPEPTIN 2 1

COPPER 104 4

CORTISOL, FREE 1 1

CORTISOL, FREE 24HR 37 2

CORTISOL,SALIVA 4 1

COXSACKIE A AB 1 1

COXSACKIE B VIRUS AB 1 1

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

CREATININE (U) 65 3

CREATININE RAND (U) 11 1

CRYOGLOB (REFL) 1 1

CRYOGLOB EVAL 21 1

CRYOGLOBULIN,%CRYO 27 1

CRYP.AG L.A. W/TITER 10 1

CULT,FUN,SKIN,W/SMR 13 1

CULT,FUNGUS,OTHER 18 1

CULTURE FUNGUS BLOOD 1 1

CULTURE FUNGUS S/H/N 6 1

CULTURE, VIRUS 2 1

CYCLOSP TR FPIA 9 1

CYP2D6 1 1

CYSTATIN C W/EGFR 1661 60

DENGUE FEVER IGG 3 1

DENGUE FEVER IGM 3 1

DESMOGLEIN AB 1 1

DEXAMETHASONE 3 1

DHEA, LC/MS/MS 8 1

DHEA-SULFATE 30 2

DIHYDROTESTOSTERONE 1 1

DIPHTHERIA ANTITOXOID 3 1

DIRECT LDL 9 1

DM,PHOSPHATIDYELTH,B 27 1

DONOR HTLV I/II 5 1

DONOR,HIV 1/HBV/HCV 2 1

DRUG ABUSE PANEL 8, W CON 14 1

DRVVT 1:1 MIX 11 1

DRVVT CONFIRM 77 3

DRVVT W/RFL PHOS.NEU 215 8

EBV AB PANEL 32 2

EBV DNA QT. PCR 18 1

EHRLICHIA CHAF AB 3 1

ELASTASE EL1, STOOL 14 1

ELECTROLYTES (FECES) 9 1

ENDOMYSIAL IGA AB 9 1

ERYTHROCYTE PORPHY 3 1

ERYTHROPOIETIN 189 7

ESTRADIOL 268 10

ESTRADIOL,EXTRACTION 18 1

ESTRIOL,SERUM 13 1

ESTROGEN, TOTAL (S) 82 3

ESTRONE 13 1

FACTOR II ACTIVITY 20 1

FACTOR V (LEIDEN) 101 4

FACTOR VII ACTIVITY 6 1

FACTOR VIII ACT CLOT 24 1

FACTOR X ACTIVITY 7 1

FACTOR X CHROMOGENIC 1 1

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

FACTOR XI ACTIVITY 4 1

FACTOR XII ACTIVITY 2 1

FECAL FAT, QUAL 46 2

FECAL LIPIDS, TOTAL 3 1

FENTANYL NORFENTANYL 7 1

FIBRIN SPLIT PROD QN 1 1

FISH CML/ALL BCR/ABL 12 1

FISH IGH/CCND1 2 1

FISH,B-CELL CLL PNL 10 1

FLECAINIDE 2 1

FOLATE, RBC 154 6

FRUCTOSAMINE 52 2

FUNGAL ID, MOLDS 5 1

FUNGAL ISOLATE ID 11 1

FUNGITELL(1-3)B-D-GL 5 1

G-6-PD (B) 30 2

GABAPENTIN, PLASMA 1 1

GAD-65 AB 84 3

GAD65 AB ASSAY, CSF 1 1

GAST,PARIETAL CELL AB 1 1

GASTRIN 2 1

GBM ANTIBODY 23 1

GLIADIN AB IGG 1 1

GLUCAGON 1 1

GLUTEN IGG 3 1

HANTAVIRUS AB,ELISA 3 1

HAPTOGLOBIN 129 5

HBSAG CONFIRMATION 2 1

HBV DNA QUANT 53 2

HCG, TOTAL, QN 36 2

HCV GENOTYPE LIPA(R) 41 2

HCV RNA BY PCR,QT 32 2

HDL SUBCLASSES 3 1

HEMOGLOBINOPATHY 38 2

HEMOSIDERIN STAIN 1 1

HEP A AB, TOTAL 289 11

HEP A AB,W/REFL IGM 1 1

HEP A IGM AB 22 1

HEP B CORE IGM AB 35 2

HEP B SURF AG W/CONF 32 2

HEP BE AB 41 2

HEP BE AG 41 2

HEP DELTA VIRUS AB 11 1

HEP INDUCED PLAT AB 7 1

HEPARIN, ANTI XA 6 1

HEREDITARY HEMO 56 2

HERPES VIRUS8 DNA QN 2 1

HEXAGONAL PHASE CONF 2 1

HGB INDICES 38 2

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

HGH 11 1

HHV 6 DNA,QL RT-PCR 1 1

HIAA, 5 (U) 1 1

HIST REL 2 1

HISTOPLASMA AB BY ID 7 1

HISTOPLASMA AB, CF 7 1

HISTOPLASMA GALAC AG 8 1

HIV 1 CORE TROPISM 1 1

HIV 1 RNA, QL RT PCR 11 1

HIV 1/2 AB DIFF W/RF 22 1

HIV-1 RESISTANCE 2 1

HIV-1 RNA,QN,RT PCR 241 9

HIV1 PROVIRAL COREC TROP 3 1

HLA-B*15:02 1 1

HLA-B*5701 TYPING 2 1

HLA-B27 ANTIGEN 291 11

HMGCR AB (IGG) 2 1

HOMOCYSTEINE 1 1

HSV 1 IGG 2 1

HSV 1/2 DNA QN PCR 8 1

HSV 1/2 IGG TYPE SP 267 10

HSV 1/2 W/REFL 8 1

HSV 2 IGG INHIBITION, IA 4 1

HSV CULT 11 1

HSV TYPE 1 & 2, PCR 1 1

HSV2 INHIBITION 2 1

HUNTINGTON'S DISEASE 6 1

HYDROCODONE AND MTB 268 10

HYPER PNEUMO EVAL 1 1

HYPOGLYCEMIC PAN;SP 1 1

IA-2 ANTIBODY 6 1

IGF I, ECL 33 2

IGG SUBCLASS PANEL 69 3

IGG SYNTHESIS/INDEX 8 1

IGVH MUTATION 3 1

IL-6 7 1

IMCAP, CLAM (F207) 1 1

IMCAP, GLUTEN (F79) 2 1

IMMUNOFIX, UR 25 1

IMMUNOFIXATION, SERUM 328 12

IMMUNOGLOBULIN A 261 10

IMMUNOGLOBULIN D 1 1

IMMUNOGLOBULIN E 18 1

IMMUNOGLOBULIN G 239 9

IMMUNOGLOBULIN M 231 9

INCUBATED PTT LA MIX 7 1

INFLIXIMAB ADA IBD 1 1

INFLIXIMAB LEVEL IBD 1 1

INHIBIN B 1 1

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

INSULIN 145 6

INSULIN ABS, HIGHLY 16 1

INTERLEUKIN 2 RECP. 2 1

INTRINSIC FACTOR AB 5 1

IODINE SERUM,PLASMA 4 1

ISLET CELL AB TITER 1 1

ISLET CELL RFX TITER 19 1

JAK2 EXON 12 MUTATN 16 1

JAK2 V617F MUTATION 119 5

JC VIRUS DNA QN PCR 36 2

JO-1 ANTIBODY 59 3

KAPPA/LAMBDA (U) 35 2

KAPPA/LAMBDA W/RATIO 249 9

KIT D816 MUT ANAYL 1 1

L PNUEMO IGM 13 1

LACOSAMIDE 11 1

LACTOFERRIN,QL,STOOL 14 1

LAMOTRIGINE 14 1

LD ISOENZYMES 1 1

LD, SYNOVIAL FLUID 1 1

LDH, TOTAL 1 1

LEAD (U) 3 1

LEAD, (B) 89 4

LEGIONELLA CULTURE 71 3

LEISHMANIA AB (IGG) 1 1

LEU & LYM 22 MARKERS 93 4

LEU & LYM 24 MARKERS 3 1

LEU & LYM 25 MARKERS 2 1

LEU & LYMP 26 MARKERS 2 1

LEVETIRACETAM IA 161 6

LIVER CYTOSOLIC IGG 1 1

LIVER FIBROSIS 130 5

LKM-1 ANTIBODY(IGG) 12 1

LUPUS ANTICOAG HEX 24 1

LUPUS ANTICOAG W/RFL 128 5

LYME AB W/REFL BLOT 75 3

LYME DIS IGG/M BLOT 6 1

LYME IGG,WB CSF 3 1

LYME IGM,WB CSF 3 1

LYMPH SUBSET PNL 2 229 9

LYSOZYME, SERUM 3 1

M PNEUMO IGG AB 24 1

M. PNEUM IGM AB 24 1

MAG IGM 33 2

MEASLES AB IGG,EIA 7 1

MEASLES AB IGM, IF 8 1

MERCURY (B) 73 3

METANEPHRINES,FRACT 76 3

METANPH.24 HR URINE 50 2

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

METANPH.RANDOM URINE 4 1

METHADONE CONFIRMATION SE 8 1

METHOTREXATE 1 1

METHYLMALONIC ACID 42 2

METHYLMALONIC ACID U 2 1

MISC-ARUP 1 1

MISC-CHANTILLY 29 2

MISC-MAYO 6 1

MITOCHONDRIAL M2 42 2

MIXING STUDY 16 1

MOG AB TITER, SERUM 1 1

MOG AB W/RFL TITER,S 15 1

MOLD SUSCEPT,5 DRUGS 8 1

MORPHINE 49 2

MPL MUTATION 25 1

MSA AB PANEL 88 4

MTHFR, DNA MUTATION 3 1

MUMPS V AB(IGM) 4 1

MUMPS VIRUS IGG, EIA 14 1

MUSK QN AB TITER 81 3

MYCO, BLOOD CULTURE 1 1

MYCO/UREA CULT. 3 1

MYCOBACT SM CULT 50 2

MYCOPHENOLIC ACID, S 1 1

MYCOPLASMA PNEU.PCR 1 1

MYELIN IGG AB 2 1

MYELOPEROXIDASE AB 278 10

MYOGLOBIN 1 1

MYOGLOBULIN, URINE 66 3

N TELOPEPTIDE,SERUM 1 1

NICOTINE/COTININE SP 15 1

NICOTINE/COTININE U 5 1

NOROVIRUS RNA,RT PCR 5 1

NORTRIPTYLINE 3 1

NOTCH3 SEQ TEST 21 1

NUCLEOTIDASE, 5' 21 1

OLIGOCLONAL BANDING 8 1

ORG ACID COMP QUANT 2 1

OROTIC ACID, URINE 1 1

OSMOLALITY, FECES 2 1

OVA AND PARASITE 119 5

OXCARBAZEPINE 19 1

OXYCODONE QN 31 2

P-ANCA TITER 6 1

P190 BCR ABL1 44 2

P210 BCR ABL1 60 3

PARANEO AUTOAB EVAL 2 1

PARANEOPLASTIC IFA 20 1

PARVO B19 IGG/IGM 8 1

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

PDM TEST 01 208 8

PFAS (FOREVER CHEM)9 1 1

PHENYTOIN, FREE 11 1

PHOSPHATIDYLETHANOL 4 1

PLA2R AB, ELISA 6 1

PLA2R AB, IFA 20 1

PLATELET AB, DIRECT 3 1

PLATELET COUNT 3 1

PLT AB SCREEN SERUM 12 1

PNH W/FLAER (HS) 4 1

PORPH FRAC, 24HR (U) 4 1

PORPHOBILINOGEN, 24HR (U) 5 1

PORPHOBILINOGEN, RAND (U) 6 1

PORPHYRINS, TOT (P) 8 1

PRA LC/MS/MS 169 7

PREGABALIN 7 1

PRIMIDONE 2 1

PROBNP 5 1

PROCAINAMIDE 3 1

PROCOLLAGEN TYPE I 2 1

PROGESTERONE 60 3

PROINSULIN 1 1

PROPAFENONE 1 1

PROTEIN C, ACTIVITY 82 3

PROTEIN C, ANTIGEN 28 1

PROTEIN ELECT W/REFL 634 23

PROTEIN ELECTRO, (U) 73 3

PROTEIN ELECTRO. 71 3

PROTEIN S ACT. ANT TOTAL 26 1

PROTEIN S AG, TOTAL 7 1

PROTEIN S, ACTIVITY 48 2

PROTEINASE-3 AB 277 10

PROTH. TIME MIX CORR 3 1

PROTHROMBIN GENE 71 3

PROTOPORPHYRIN, ZINC 3 1

PS/PT AB (IGG) 220 8

PS/PT AB (IGM) 220 8

PTH,INTACT & CALCIUM 29 2

PTH-RELATED PROTEIN 41 2

PTT MIX/CORR/INCUBAT 10 1

PTT, ACTIVATED 16 1

PTXPLNT,HBV,RT PCR,S 1 1

PYRUVATE (B) 51 2

Q FEV.IGG PHSI TITER 1 1

Q FEVER IGG PHSI SCR 2 1

Q FVR IGG PHS II SCR 2 1

Q FVR IGG PHSII TITR 1 1

Q FVR IGM PHSEI SCR 2 1

Q FVR IGM PHSII SCRN 2 1

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

QT THYROGLOB W/O ATA 91 4

QUANTIFERON(R) PL 4T 1 1

QUEST AD DETECT(TM), BETA 2 1

QUESTASSURED VIT D 1 1

QUETIAPINE;SP 1 1

RABIES VACCINE RESP 2 1

RAPAMYCIN-SIROLIMUS 19 1

RHEUMATOID FACTOR,SC 1 1

RISTOCETIN COFACTOR 16 1

RMSF IGG/IGM W/REFL 9 1

RNA POLYMERASE III 2 1

RPR MONITOR W/REFL 141 6

RPR TITER 77 3

RT3 BY LC/MS/MS 77 3

RUBELLA IGM AB 18 1

RUBELLA IMMUNE 5 1

S.PNEUM IGG(14 SERO) 17 1

SALMONELLA AB EIA 2 1

SCHISTOSOMIASIS IGG 1 1

SCL-70 51 2

SELENIUM, B 6 1

SEROTONIN REL. ASSAY 12 1

SEROTONIN, SERUM 6 1

SHBG 348 13

SICKLE CELL SCREEN 4 1

SJOGREN'S ANTIBODIES 45 2

SJOGRENS AB (SS-B) 33 2

SM ANTIBODY 7 1

SM/RNP ABS 5 1

SMA 2+0 1 1

SMOOTH MUSC RFX/TIT 50 2

SMOOTH MUSCL TITER 3 1

SOLUBLE LIVER AG ABS 2 1

SS A RO AB(IGG)EIA 33 2

STONE ANALYSIS 65 3

STONE RISK DIAG PROF 39 2

STRIATED AB TITER 2 1

STRIATED MUSCLE W/REFL 20 1

STRONGYLOIDES IGG AB 1 1

SUS. YEAST COMP PNL 19 1

SUSCEPT AER MIC 8 1

SUSCEPT,PNL ANAEROBE 2 1

T CELL RECEPT TCR 1 1

T-3 UPTAKE 58 3

T-3, FREE 589 22

T-3, TOTAL 160 6

T-4 (THYROXINE) 80 3

T.VAGINALIS RNA,MALE 44 2

TACROLIMUS, LC/MS/MS 148 6

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

TCELL RECEPT GAMMA 2 1

TESTOSTERONE, FREE 1313 47

TESTOSTERONE,TOTALMS 315 12

TETANUS ANTITOXOID 3 1

THIOPURINE METAB 2 1

THROMBIN TIME 12 1

THROMBOPOIETIN (TPO) 2 1

THYROGLOBULIN AB 207 8

THYROID PEROXID AB 143 6

TOPIRAMATE 6 1

TOXO IGG AB 6 1

TOXO IGM EIA 6 1

TPMT GENOTYPE 1 1

TRAB 22 1

TRAMADOL AND METABOL 812 29

TRICHOMONAS VAG RNA, QL 33 2

TRYPTASE TOTAL 5 1

TSIG 51 2

TTG IGA 62 3

TTG IGG 1 1

TUBEROUS SCLEROSIS 1 1

URORISK DIAG PROF 1 1

VALPROIC ACID, FREE 1 1

VDRL, CSF 9 1

VEDOZ QN AB 1 1

VGCC AB ASSAY 33 2

VGCC TYPE N AB 29 2

VGKC ANTIBODY 18 1

VIP 3 1

VISCOSITY 3 1

VITAMIN A (RETINOL) 30 2

VITAMIN B1,LCMSMS,P 139 5

VITAMIN B1,THIAMINE 1 1

VITAMIN B2 15 1

VITAMIN B3 9 1

VITAMIN B6 39 2

VITAMIN B7 (BIOTIN) 3 1

VITAMIN C 18 1

VITAMIN D,1,25 88 4

VITAMIN E 26 1

VITAMIN K, PLASMA 15 1

VLC FATTY ACIDS 3 1

VON WILLEBRAND AG 16 1

VON WILLEBRAND, MULT 6 1

VZV AB IGM 4 1

VZV DNA QN PCR 5 1

VZV IGG AB 9 1

WEST NILE VIRUS CSF 7 1

WEST NILE VIRUS,(S) 8 1

TEST DESCRIPTION TOTAL TEST COUNT

( 28 MONTHS: JAN 2023 - APR 2025)

MONTHLY

ESTIMATE

(ROUNDED UP)

WHIPPLE'S DNA PCR 1 1

YEAST ID 20 1

YEAST ID AND SUSCEPT 20 1

YO AB SCR W/REFLEX 1 1

YO AB WB, SERUM 1 1

ZINC (P) 87 4

ZNT8 ANTIBODY 13 1

(END OF STATEMENT OF WORK)

B.3 PRICE/COST SCHEDULE

ITEM INFORMATION

ITEM

NUMBER

DESCRIPTION OF

SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT

12.00 MO __________________ __________________

Reference Lab Testing for the Amarillo VA Health Care

System in accordance with the Statement of Work. See Price List (Attachment 1) for Test Pricing. (Estimated Quantities).

Contract Period: Base POP Begin: 01-01-2026 POP End: 12-31-2026 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories PRODUCT/SERVICE CODE: Q301 - Medical - Reference Laboratory Testing

System in accordance with the Statement of Work. See Price List (Attachment 1) for Test Pricing. (Estimated Quantities).

Contract Period: Option 1 POP Begin: 01-01-2027 POP End: 12-31-2027 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories

System in accordance with the Statement of Work. See Price List (Attachment 1) for Test Pricing. (Estimated Quantities).

Contract Period: Option 2 POP Begin: 01-01-2028 POP End: 12-31-2028 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories

System in accordance with the Statement of Work. See Price List (Attachment 1) for Test Pricing. (Estimated Quantities).

Contract Period: Option 3 POP Begin: 01-01-2029 POP End: 12-31-2029 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories

System in accordance with the Statement of Work. See Price List (Attachment 1) for Test Pricing. (Estimated Quantities).

Contract Period: Option 4 POP Begin: 01-01-2030 POP End: 12-31-2030 PRINCIPAL NAICS CODE: 621511 - Medical Laboratories

GRAND TOTAL __________________

B.4 INTRODUCTION

In the spirit of the Federal Acquisition Streamlining Act, the Department of Veterans Affairs (DVA) and hereby enter into a cooperative agreement, otherwise referred to as a Blanket Purchase Agreement (BPA), to further reduce the administrative costs of acquiring supplies/services from the General Services Administration (GSA) Federal Supply Schedule Contract # TBD. Federal Supply Schedule contract BPA's eliminate contracting and open market costs such as: search for sources; the development of technical documents, solicitations and the evaluation of offers. Teaming Arrangements are permitted with Federal Supply Schedule Contractors in accordance with Federal Acquisition Regulation (FAR) 9.6.

The agreement details all Services with accompanying prices and descriptions, which may be ordered under this BPA.

This BPA expires on 12-31-2030 or such later ending date as determined by the exercise of any option.

All orders placed against this BPA are subject to the terms and conditions of all the clauses and provisions in full text or incorporated by reference in this document.

B.5 TERMS AND CONDITIONS

Pursuant to GSA FSS Schedule Contract # TBD, regarding Blanket Purchase Agreements, the Contractor agrees to the following terms of a Blanket Purchase Agreement (BPA) EXCLUSIVELY WITH the Department of Veterans Affairs:

B.6 ADMINISTRATIVE DATA

A Blanket Purchase Agreement (BPA) is hereby established between and the Department of Veterans Affairs under the following terms and conditions incorporated in this BPA and GSA Federal Supply Schedule contract:

Primary Point of Contact:

Alternate Point of Contact:

DUNS NUMBER:

Cognizant Office (Include complete address):

Network Contracting Office 17

5441 Babcock Road Ste. 302

San Antonio TX 78240

B.7 PRICING DATA

1. The prices included on the BPA list (or applicable "discounted" rates submitted in a proposal response to an RFQ resulting in award) that are in effect on the effective date of an order shall govern that order's basic performance period. With regard to any option years, which are later exercised, the proposed option year rates as incorporated into the order award are in effect until such time, if applicable, that the contractor has been authorized a rate increase culminating from a negotiation with the Contracting Officer.

2. The BPA holder can voluntarily reduce offered prices at any time by giving 24-hour advance notice (by facsimile or electronic-mail) to the Department of Veterans Affairs/Contracting Officer.

This BPA also allows for additional discounts if a "large order" is placed at one time. An advanced notice is not required for discounts offered for only an individual order. Whether an order is large enough to warrant such a discount is subject to the discretion of the BPA holder.

3. The BPA holder may also increase BPA prices at any time. Any BPA price increase shall not take effect until the Department of Veterans Affairs Contracting Officer receives written notification (U.S. mail, facsimile, or electronic-mail). Any order already issued shall not be affected by any change to BPA pricing. The prices offered under this BPA will undergo annual review by the Department of Veterans Affairs Contracting Officer.

B.8 NONPERSONAL SERVICES

a. In performance of this contract, the BPA holder will provide services as required by program offices to support management of their overall mission. This will be based upon the order's performance work statement for the specific effort. Orders will be formally issued to the BPA holder as opposed to individual BPA holder employees.

b. The services required under the Agreement constitute professional and management services within the definition provided by FAR 37.201. Under this Agreement the Government will obtain professional services, which are essential to the Department of Veterans Affairs mission but not otherwise available within Department of Veterans Affairs.

c. The Government will neither supervise BPA holder employees nor control the method by which the BPA holder performs the required tasks. Under no circumstances shall the Government assign tasks to, or prepare work schedules for, individual BPA holder employees.

It shall be the responsibility of the BPA holder to manage their employees and to guard against any actions that are of the nature of personal services, or give the perception of personal services. If the BPA holder feels that any actions constitute, or are perceived to constitute personal services, it shall be the BPA holder's further responsibility to notify the Contracting Officer immediately.

d. These services shall not be used to perform work of a policy/ decision making or management nature. All decisions relative to programs supported by BPA holders will be the sole responsibility of the Government. Support services will not be ordered to circumvent personnel ceilings, pay limitations, or competitive employment procedures.

B.9 AUTHORIZED LIMITS

The Government estimates, but does not guarantee, that individual BPA Orders placed against this Agreement may reach $485,000.00/per Order. This Order Limit may be increased by mutual agreement of the parties as necessary, in whole or part. The authorized Ceiling Limit of the Agreement is set at $2,500,000.00 over the period covered by the Agreement; this ceiling is also not a guarantee. The Ceiling Limit may also be raised in association with order Limit increases or other conditions which, by mutual agreement of the parties, maybe considered necessary. Authorization for individual Task Orders above the stated Task Order and/or Ceiling Limits must be coordinated through the Contracting Officer before larger valued orders can be issued and prior to commencement of work. All unauthorized work, regardless of amount, will be processed through the ratification process.

B.10 OBLIGATION OF FUNDS

This BPA does not obligate any funds. The Government is obligated only to the extent of authorized orders actually issued under the BPA by the Contracting Officer.

B.11 PERIOD OF PERFORMANCE

This BPA expires on 12-31-2030 or such later ending date as determined by the exercise of any option.

B.12 AUTHORIZED INDIVIDUALS

Individuals Authorized to Place Orders:

DVA authorizes the following entities to place orders:

Network Contracting Office 17 Contracting Officers

B.13 ORDER FORMAT

Orders will be placed against this BPA via e-mail, Electronic Data Interchange (EDI), FAX, or in hardcopy format. Each individual BPA Task Order will describe the tasks, services and deliverables required.

B.14 AUTHORIZED REPRESENTATIVES

The primary Contracting Officer (CO) for this Agreement is:

Jose Campa

Department of Veterans Affairs Network Contracting Office 17 5441 Babcock Road Ste. 302 San Antonio, TX 78240

Jose.Campa@va.gov

The Primary Contracting Officer's Representative (COR) for projects under this Agreement is:

The Secondary Contracting Officer's Representative (COR) for projects under this Agreement is:

The Primary and/or Secondary COR will be responsible for technical monitoring of the contractor's performance and deliveries. The COR and the Contractor's Representative shall work together to ensure that all contractual requirements are being met. The COR will interpret specifications or technical portions of the work. The COR is not authorized to perform, formally or informally, any of the following actions:

(1) Promise, award, agree to award, or execute any contract, contract modification, or notice of intent that changes or may change this contract;

(2) Waive or agree to modification of the delivery schedule;

(3) Make any final decision on any contract matter subject to the Disputes Clause;

(4) Terminate, for any reason, the contractor's right to proceed;

mailto:Jose.Campa@va.gov

(5) Obligate in any way, the payment of money by the Government. Only a warranted Contracting Officer is authorized to obligate funds on this or any other contract action.

The contractor shall immediately notify the Contracting Officer in writing if the COR has taken an action (or fails to take action) or issues directions (written or oral) that the contractor considers to exceed the above limitations.

The contractor shall provide the Contracting Officer information copies of all correspondence to the COR.

B.15 FEDERAL HOLIDAYS

Unless specifically authorized in writing by the Contracting Officer, no services will be provided and no charges will be incurred and/or billed to any order on this contract on any of the Federal Holidays listed below.

New Year’s Day Labor Day Birthday of Martin Luther King, Jr. Columbus Day Washington’s Birthday Veterans' Day Memorial Day Thanksgiving Day Juneteenth Christmas Day Independence Day

B.16 INVOICES

a. Inspection and acceptance shall be accomplished as follows: The Government, for all services furnished under any resulting order, hereby designates the COR in the program office as the point of final inspection and acceptance. The BPA holder will submit each invoice, including all back-up data, to the Contracting Officer (CO) for review and signature. When the CO receives an accurate and complete invoice, he/she will return a signed copy to the BPA holder within five (5) working days. If the invoice is incomplete or inaccurate, the CO will return the unsigned invoice to the BPA holder for correction. The Contracting Officer will then forward the signed invoice to the Chief Financial Officer (CFO) for payment. Final payment for each order will be accomplished by final invoice accompanied by a receiving report.

b. An itemized invoice shall be submitted to the CO at least monthly or upon expiration of this BPA, whichever occurs first, for all deliveries made during a billing period and for which payment has not been received. Copies of delivery tickets shall support these invoices.

"Approved-for-payment" invoices will be submitted to the payment address specified on each individual order issued under this BPA.

B.17 PRECEDENCE

The Terms and conditions included in this BPA apply to all purchases made pursuant to it. In the event of an inconsistency between the provisions of this BPA and the Contractor's invoice, the provisions of this BPA will take precedence.

SECTION C - CONTRACT CLAUSES

C.1 FSS RFQ INTRODUCTORY LANGUAGE

The terms and conditions of the contractor's FSS contract (including any contract modifications) apply to all Blanket Purchase Agreements (BPA) and task or delivery orders issued under the contract as a result of this RFQ. When a lower price has been established, or when the delivery terms, FOB terms, or ordering requirements have been modified by the BPA or task/delivery order, those modified terms will apply to all purchases made pursuant to it and take precedence over the FSS contract. Any unique terms and conditions of a BPA or order issued under the contract that are not a part of the applicable FSS contract will govern. In the event of an inconsistency between the terms and conditions of a BPA or task/delivery order and the Contractor's FSS terms, other than those identified above, the terms of the FSS contract will take precedence.

C.2 52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)

This contract incorporates one or more clauses by reference, with the same force and effect as…